Professionals from all areas of biotechnology convened for the 20th annual BIO CEO & Investor Conference held at New York’s Marriott Marquis February 12th and 13th. Looking for deals, partnerships and collaborations, attendees participated in BIO One-on-One Partnering™, networked, listened and learned during a busy two days.
As one of the largest investor conferences focused on established and emerging publicly-traded and select private biotech companies, the event drew an enthusiastic group ready to make deals and find the right partners to move innovation to the marketplace. The key relationship-building was reflected in the 2,700 individual meetings that took place during the conference, scheduled through the partnering system.
We talked with several attendees to get their take on the conference
Things were very busy at BIO’s buzz center where interviews with thought-leaders focused on breakthrough technologies and the investment climate for biotechnology.
There was no shortage of twitter activity underscoring the impact of this event.
The market is up. Could it be thanks to #BIOCEO18 also being in NYC
– Rob Wright (@RfwrightLSL) February 12, 2018
Got to chit chat with biotech veteran Deborah Dunsire at #BIOCEO18 this a.m. Her take on the current biotech investment outlook: “It’s not the boom of 2013, but it’s not the nuclear winter of 2009 either.”
– Jessica Merrill (@Jessicaemerrill) February 13, 2018
Not a whole lot of new opioid pain meds in development (16), yet 109 non-opioids in development. Speaker says that’s still not enough as approvals of new pain meds is less than 2% #BIOCEO18 pic.twitter.com/30NXeE54ac
– Rob Wright (@RfwrightLSL) February 13, 2018
.@barbara_ryan12: “This will probably be a record year in terms of M&A and consolidation.” @sciam #BIOCEO18 Summit on #biotech and #Cancer. pic.twitter.com/uZgDXqldcB
– Michael Heinley (@mheinley) February 13, 2018
Middle ground -platform vs product companies – but platform brings critically important innovations – we can’t underestimate it. @IAmBiotech #BIOCEO18
– Donna LaVoie (@dlavoie02) February 12, 2018
#BIOCEO18 key takeaway from M&A/IPO session seems to be expectation that deals will shift back to targeting product companies rather than platform companies (as valuation is becoming too high for highly unpredictably cash flows of platform companies)$IBB $BIB $XBI
– Jack Allen (@datamonitor_JA) February 12, 2018
Great day at #BIOCEO18 @MichaelSierra16 @LEOscitech with other thought leaders discussing the crossroads of technology and #dermatology in the “Advances in Dermatology” panel pic.twitter.com/YSZa8YVMxf
– leo-scitech (@LEOscitech) February 12, 2018
Current IPO market – 2x deals in 2018 vs 2017 post JPM18 @IAmBiotech #BIOCEO18
– Donna LaVoie (@dlavoie02) February 12, 2018
“Our mission is supporting national advocacy, science and research while supporting the actionable results of promoting women in science” –@AWISNational
0 Comments
Comments are closed.